OR WAIT null SECS
July 24, 2023
The paper highlights the potential of AI in the medicinal product lifecycle and the approach that developers should take with it.
Sanofi and Recludix Pharma’s deal centers on developing treatments for various immunological and inflammatory diseases.
July 21, 2023
The proposed spin-off of Sandoz into an independent entity has been approved by Novartis’ board of directors.
The expanded deal, now potentially worth more than $1.2 billion, will work to develop in vivo therapies, including sickle cell disease.
July 20, 2023
Novartis’ acquisition of biotech company DTx Pharma boosts its neuroscience pipeline and expands its capabilities in RNA-based therapeutics.
These recommendations will keep key antibiotics for respiratory infections available when they are needed most.
July 14, 2023
German manufacturer metabion is conducting a multi-million euro expansion of its oligonucleotide manufacturing capacity in Munich East.
July 13, 2023
The agency is reviewing the medicines after receiving reports of self-injury and suicidal thoughts in patients using the type 2 diabetes treatments.
July 07, 2023
Camena Bioscience has completed $10 million in Series A financing on the back of growing demand for DNA synthesis.
Eurofins Genomics Blue Heron’s novel mRNA synthesis service is designed for customizable applications.